No biomarker
No biomarker
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
|
PD-L1 expression
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
|
PD-L1 expression
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
nivolumab
Sensitive: B - Late Trials
|
EGFR overexpression
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
erlotinib
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
tislelizumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
nivolumab + ipilimumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
tislelizumab
Sensitive: B - Late Trials
|
NTRK3 fusion
NTRK3 fusion
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
larotrectinib
Sensitive: C1 - Off-label
|
NTRK2 fusion
NTRK2 fusion
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
larotrectinib
Sensitive: C1 - Off-label
|
NTRK1 fusion
NTRK1 fusion
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
larotrectinib
Sensitive: C1 - Off-label
|
EGFR mutation
EGFR mutation
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
afatinib
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
trastuzumab
Sensitive: C1 - Off-label
|
EGFR amplification
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
afatinib
Sensitive: C2 – Inclusion Criteria
|
NRG1 overexpression
NRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
AV-203
Sensitive: C3 – Early Trials
|
NDRG1 overexpression
NDRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil
Resistant: C3 – Early Trials
|
SGK1 overexpression
SGK1 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil
Resistant: C3 – Early Trials
|
AFAP1-AS1 overexpression
AFAP1-AS1 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
FP
Resistant: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
camrelizumab
Sensitive: C3 – Early Trials
|
TLR signature
TLR signature
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
tislelizumab
Sensitive: C3 – Early Trials
|
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil
Sensitive: C3 – Early Trials
|
DKK1 overexpression
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
pembrolizumab + DKN-01
Sensitive: C3 – Early Trials
|
DKK1 overexpression
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
DKN-01
Sensitive: C3 – Early Trials
|
NFKB1 expression
NFKB1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
rivoceranib
Sensitive: C3 – Early Trials
|
KDR expression
KDR expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
rivoceranib
Sensitive: C3 – Early Trials
|
PD-L1 overexpression + CCL5 overexpression
PD-L1 overexpression + CCL5 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
Immunotherapy
Sensitive: C3 – Early Trials
|
PD-L1 underexpression
PD-L1 underexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
toripalimab + surufatinib
Sensitive: C3 – Early Trials
|
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin
Sensitive: C3 – Early Trials
|
MYH4 Q1210fs
MYH4 Q1210fs
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin
Sensitive: C3 – Early Trials
|
MRE11A underexpression
MRE11A underexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin
Resistant: C3 – Early Trials
|
UBQLN4 overexpression
UBQLN4 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin
Resistant: C3 – Early Trials
|
PD-L1 overexpression
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
AB122
Sensitive: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
SCT200
Sensitive: C3 – Early Trials
|
BRCA1 mutation
BRCA1 mutation
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
FOLFOX
Sensitive: C4 – Case Studies
|
CDK14 overexpression
CDK14 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin
Resistant: D – Preclinical
|
MACC1-AS1 overexpression
MACC1-AS1 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin
Resistant: D – Preclinical
|
PARP1 expression
PARP1 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
anlotinib
Sensitive: D – Preclinical
|
TP53 mutation
TP53 mutation
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
afatinib
Sensitive: D – Preclinical
|
CD31 expression
CD31 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
anlotinib
Sensitive: D – Preclinical
|
BAX expression
BAX expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
anlotinib
Sensitive: D – Preclinical
|
SOX9 overexpression
SOX9 overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
|
EGFR overexpression
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
nimotuzumab
Sensitive: D – Preclinical
|
LYPD3 expression
LYPD3 expression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
BAY1129980
Sensitive: D – Preclinical
|
PER2 underexpression
PER2 underexpression
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
cisplatin
Sensitive: D – Preclinical
|
